116 The fact that tirzepatide produces substantially greater weight loss than semaglutide, despite similar appetite suppression, 117 raises the possibility that GIP-specific adipose remodeling (rather than reduced caloric intake alone) may contribute to the weight loss observed with dual GIP/GLP-1 agonism, although whether this translates to enhanced thermogenesis or energy expenditure in humans remains unknown
Regular follow-up allows monitoring of symptom progression and treatment response
Healthcare professionals typically initiate treatment at a lower dose (0.25 mg weekly), which is an initiation dose only and not intended for glycaemic control, and gradually increase to therapeutic levels (0.5 mg or 1 mg weekly) to minimise these symptoms whilst allowing the body to adapt to the medication's effects on the digestive system
Unless Medicaid covers obesity medications, enrollees are unlikely to have access to them given the high out-of-pocket cost even at lower prices
Patients should be counseled to contact their healthcare provider if they experience specific warning signs
Pricing reflects the GMC Specialist Register plastic surgeon credential and sits above standard nurse-injector tier.